Navigation Links
Breakthrough research identifies how cells from pigs may cure diabetes
Date:9/12/2007

MINNEAPOLIS, Minn. Within three years, insulin-producing islet cells from pigs may be used in clinical trials on a path to finally cure insulin dependant diabetes.

This key finding was the discovery of Dr. Bernhard Hering, Scientific Director of the Diabetes Institute for Immunology & Transplantation at the University of Minnesota and his team, who documented their medical breakthrough in the prestigious scientific journal Nature Medicine in March of 2006.

On Thursday, September 20, at 10:00 a.m. CDT, Hering will present the latest research on pig islet xenotransplantation at the Diabetes Research and Wellness Foundation Symposium at the Hyatt Regency Minneapolis in Minneapolis, MN.

The symposium will be part of The Transplantation Societys 2007 Joint Conference (www.cts-ipita-ixa-2007.org), an international event that will unite the greatest innovators from three sections of the Transplantation Society the Cell Transplant Society (CTS), the International Pancreas and Islet Transplant Association (IPITA) and the International Xenotransplantation Association (IXA) for the first time in history. Hering also serves as the Joint Conference president.

Research has shown that the transplantation of islet cells, harvested from the pancreas of a pig, yields a long-term reversal of diabetes in monkeys, opening the path to unprecedented new opportunities for human patients with the disease. To oversee immunosuppression issues, researchers are now working to transplant porcine islets in an engineered pre-vascularized, cytoprotective and immune-privileged implantation site. This procedure has a number of advantages including:

  • Pigs will be able to provide unlimited islet tissue in a few years.

  • Pig islets from young disease-free donors are superior to cadaver human islets.

  • The actual risk of infectious disease transmission is lower with xenotransplantation of islets.

  • Bioengineering of islet implantation sites into a pre-vascularized, cytoprotective and immune-privileged site will allow for local and selective immunosuppression.

  • Promoting long-term survival of the porcine islet xenografts in humans.

As Hering and his team prepare to enter into clinical trials slated to commence within three years Spring Point Project (www.springpointproject.org), a non-profit organization, is helping to grow a population of medical grade pigs so that once the cure is realized, diabetes sufferers will find the treatment to be widely available and affordable.

Dr. Henk-Jan Schuurman, CEO of Spring Point Project, will moderate the Source Pigs for Xenotransplantation Trials Symposium on Saturday, September 15 at the Hyatt Regency Minneapolis, during the Joint Conference.

In order to have high health pigs available for clinical trials, Spring Point Project now operates a 21,000-square-foot biosecure facility in Western Wisconsin called the Diabetes Research and Wellness Foundation Islet Resource Facility. Inside, a team of highly skilled veterinarians and animal care staff is actively raising high health pigs in compliance with governmental regulations a charge that requires the pigs to be housed in an ultra clean biosecure environment, fed special food and given only purified water to drink and filtered air to breathe.

Continuing to populate our Islet Resource Facility brings us closer to meeting our ultimate goal of curing diabetes, Schuurman says. With the pigs that are currently housed in our biosecure facility, were already expediting the widespread availability of islet cell tissue so that an adequate supply of pig donors will be available for clinical islet cell transplantation trials using patients with diabetes.


'/>"/>

Contact: Molly Kersten
mkersten@r-p.com
419-241-2221
R/P Marketing Public Relations
Source:Eurekalert

Related biology news :

1. Recent breakthroughs in common adult leukemia highlighted in New England Journal of Medicine
2. Breakthrough Microarray-based Technology for the Study of Cancer
3. Leukemia Drug Breakthrough Study In New England Journal Of Medicine
4. Breakthrough method in nanoparticle synthesis paves the way for new pharmaceutical and biomedical applications
5. MUHC researchers make cancer target breakthrough
6. Breakthrough isolating embryo-quality stem cells from blood
7. Breakthrough System for Understanding Ocean Plant Life Announced
8. Major breakthrough in the treatment of cancers and infectious diseases
9. Breakthrough: Scientists create worlds tiniest organic particles
10. Sciences Breakthrough of the Year: Watching evolution in action
11. Breakthrough in micro-device fabrication combines biology and synthetic chemistry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/7/2017)... Brandwatch , the leading social intelligence company, today announces that ... uncover insights to support its reporting, help direct future campaigns, and ... youth charity will be using Brandwatch Analytics social listening and analytics ... of the topics and issues that are a priority for its ... "Until recently ...
(Date:3/2/2017)... March 2, 2017 Summary This report ... and its partnering interests and activities since 2010. ... Read the full ... Alliance since 2010 report provides an in-depth insight into the ... companies. On demand company reports are prepared upon ...
(Date:3/2/2017)... March 2, 2017 Australian stem cell and ... CYP), has signed an agreement with the Monash Lung ... Biomedicine Discovery Institute and Department of Pharmacology at Monash ... further preclinical study to support the use of Cymerus™ ... Asthma is a chronic, long term ...
Breaking Biology News(10 mins):
(Date:3/27/2017)... 27, 2017 DarioHealth Corp. (NASDAQ: DRIO), a ... big data solutions, today announced that it is now ... for U.S. consumers who want to have their DarioHealth ... signed strategic alliance agreements with partners across the U.S. ... and if approved, will supply and bill the customer,s ...
(Date:3/24/2017)... MARIETTA, Ga. , March 24, 2017 ... and biopharmaceutical company utilizing human placental tissue allografts and ... therapies for multiple sectors of healthcare, announced today  that ... New York , NY.  Parker H. ... , Chief Financial Officer, Christopher M. Cashman , ...
(Date:3/24/2017)... Research and Markets has announced the addition of the "Human ... report to their offering. ... This report analyzes the Global market for Human Embryonic ... are provided for the period 2014 through 2022. Market data and ... The report profiles 25 companies including many key and niche players ...
(Date:3/24/2017)... March 24, 2017 On Thursday, ... session at 5,817.69, down 0.07%; the Dow Jones Industrial ... the S&P 500 closed at 2,345.96, marginally dropping 0.11%. ... closed in green, 4 sectors finished in red, and ... Stock-Callers.com has initiated reports coverage on the following Biotechnology ...
Breaking Biology Technology: